News Focus
News Focus
icon url

DewDiligence

06/04/15 11:45 AM

#192077 RE: DewDiligence #191684

ABBV-JNJ—Imbruvica shows statsig PFS/OS in phase-3 trial in first-line CLL/SLL:

http://finance.yahoo.com/news/ibrutinib-imbruvica-improved-survival-treatment-132000678.html

The trial design was Imbruvica head-to-head vs chemotherapy.